Jennifer L. Good - 31 May 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Reporting relationship: President & CEO, Director
Issuer ticker: TRVI
Reported as of: 31 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Jun 2025, 16:00:29 UTC
Prior SEC filing: 25 Mar 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Christopher Galletta, attorney-in-fact

Key filing fact

Jennifer L. Good filed Form 4 for Trevi Therapeutics, Inc. (TRVI) on 03 Jun 2025.

Key facts

This page summarizes Jennifer L. Good's Form 4 filing for Trevi Therapeutics, Inc. (TRVI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Jun 2025, 16:00.

Change

Previous filing in this sequence was filed on 25 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001229245 Primary reporting owner

GOOD JENNIFER L

Relationship: President & CEO, Director
Address: C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN
Signature: /s/ Christopher Galletta, attorney-in-fact
Signature date: 03 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRVI transaction Derivative

Performance Stock Option (right to buy)

Award

Transaction value: $0
Shares: +102,000
Change %: +188%
Price: $0.000000
Shares after: 156,400
Date: 31 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 102,000
Exercise price: $2.38
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reporting person was granted a performance-based stock option on February 15, 2024, to purchase 170,000 shares of common stock. The option vested based on the attainment of established performance criteria related to the timing and successful results of the Company's Phase 2b CORAL trial of Haduvio (nalbuphine ER) in patients with chronic cough in idiopathic pulmonary fibrosis, and Phase 2 RIVER trial of Haduvio in patients with refractory chronic cough. On March 10, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the RIVER trial were satisfied, resulting in the vesting of the option as to 54,400 shares of common stock. On May 31, 2025, the Compensation Committee of the Board of Directors of the Company certified that the performance metrics related to the successful results of the CORAL trial were satisfied, resulting in the vesting of the option as to 102,000 shares of common stock.